Superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer's Disease.

Xiao-Ge LiuLun ZhangShuai LuDong-Qun LiuYa-Ru HuangJie ZhuWei-Wei ZhouXiao-Lin YuRui-Tian Liu

Published in: Journal of nanobiotechnology (2020)

These results suggest that W20/XD4-SPIONs show therapeutic benefits for AD. In combination with the early diagnostic property, W20/XD4-SPIONs present as a promising agent for early-stage AD diagnosis and intervention.

Keyphrases

iron oxide nanoparticles
early stage
randomized controlled trial
photodynamic therapy
nuclear factor
squamous cell carcinoma
inflammatory response
binding protein
toll like receptor
mild cognitive impairment
locally advanced